What is the appropriate treatment for an 82-year-old woman with a galectin‑3 level of 36.4 ng/mL who has type 2 diabetes mellitus, hypertension, hyperlipidaemia, hypothyroidism, coronary artery disease with multiple prior cardiac catheterizations, congestive heart failure, chronic kidney disease, anemia, pulmonary hypertension, anxiety, cognitive impairment, and a history of abdominal aortic aneurysm?

Treatment Approach for Elevated Galectin-3 in Complex Multimorbid Patient

This 82-year-old woman with a galectin-3 level of 36.4 ng/mL (markedly elevated, >2x the median of ~15 ng/mL) and established congestive heart failure, chronic kidney disease, type 2 diabetes, and coronary artery disease requires immediate initiation of an SGLT2 inhibitor (dapagliflozin or empagliflozin) as the cornerstone therapy, with strong consideration for adding finerenone given her CKD. 1, 2

Understanding the Clinical Context

The galectin-3 level of 36.4 ng/mL is substantially elevated and independently predicts:

• Progression of heart failure 3, 4
• Worsening kidney function 3, 5
• Increased cardiovascular mortality 6, 4
• Higher absolute risk of adverse outcomes 3

Critical insight: While galectin-3 itself is not a direct treatment target, this markedly elevated level (well above the median of 14.9 ng/mL) identifies a patient at very high risk who will derive greater absolute benefit from evidence-based therapies 3.

Primary Pharmacologic Interventions

1. SGLT2 Inhibitor (Immediate Priority)

Initiate dapagliflozin 10 mg daily OR empagliflozin 10 mg daily 1, 2

Rationale specific to this patient:

• Heart failure benefit: Reduces HF hospitalization and cardiovascular mortality by 35% in HFrEF, regardless of diabetes status 1, 2
• Kidney protection: In patients with elevated galectin-3, dapagliflozin showed greater absolute risk reduction for kidney disease progression (ARR 1.9% in highest galectin-3 quartile vs 0.6% in lowest) 3
• Works in CKD: Effective down to eGFR ≥20 mL/min/1.73 m² 2, 7
• Diabetes management: Despite being off diabetes medications, this addresses the underlying metabolic dysfunction 1, 8

Practical considerations:

• Can initiate even if eGFR is 20-30 mL/min/1.73 m² (though DAPA-HF excluded <30) 2
• Monitor for genital mycotic infections (10-15% risk in women) 2
• No dose adjustment needed for kidney function
• Continue even if patient develops acute illness (no "sick day" discontinuation needed for heart failure indication)

2. Finerenone (Strong Consideration)

Add finerenone 10-20 mg daily (dose based on eGFR and potassium) 1, 8, 7

Rationale:

• Specifically indicated for type 2 diabetes with CKD
• Reduces cardiovascular death, MI, stroke, or HF hospitalization by 13% 1
• Reduces kidney disease progression by 18% 7
• Complementary mechanism to SGLT2 inhibitors (can use both) 1

Key monitoring:

• Check potassium before initiation and regularly thereafter
• Discontinuation rate for hyperkalemia is 2.3% vs 0.9% placebo 7
• Requires eGFR ≥25 mL/min/1.73 m² and UACR ≥30 mg/g 7

3. Optimize Foundational Heart Failure Therapy

ACE inhibitor or ARB (if not already on maximum tolerated dose) 1, 9

• Essential for asymptomatic stage B heart failure progression prevention
• Target maximum tolerated dose
• Caution: In elderly patients with CAD, avoid lowering diastolic BP <60 mmHg 9

Beta-blocker (if not already on maximum tolerated dose) 1, 9

• Carvedilol or metoprolol succinate preferred
• Reduces mortality by 23% post-MI with reduced LVEF 1
• Essential for secondary prevention given multiple prior catheterizations 9

Critical Clinical Caveats

Blood Pressure Management

Given this patient's age (82), multiple comorbidities, and CAD history:

• Target BP <130/80 mmHg for diabetes, CKD, and CAD 9
• Avoid diastolic BP <60 mmHg - increases risk in elderly diabetics with CAD 9
• Lower BP slowly to avoid ischemia 9

Anemia Considerations

With established anemia and CKD:

• Consider IV iron replacement if iron deficiency present 10
• Check iron studies, ferritin, and transferrin saturation
• IV iron improves symptoms and quality of life in HF patients 10

Diabetes Management

Despite being "on no current medications":

• SGLT2 inhibitor serves dual purpose - cardiovascular/renal protection AND glycemic control 1
• Monitor HbA1c - may need additional therapy if inadequate control
• GLP-1 RA could be considered if obesity present and HFpEF component 1

What NOT to Do

Avoid calcium channel blockers (especially non-dihydropyridines like diltiazem/verapamil) if LVEF <50% - may worsen heart failure 10

Do not delay SGLT2 inhibitor waiting for "optimization" of other therapies - start early given high-risk profile 2

Do not use galectin-3 for serial monitoring - its primary value is risk stratification at baseline, not treatment monitoring 11, 12

Monitoring Strategy

Initial (first 2-4 weeks):

• Potassium and creatinine (especially if adding finerenone)
• Blood pressure (ensure not dropping too low)
• Volume status and symptoms

Ongoing (every 3-6 months):

• eGFR and UACR (kidney function trajectory)
• HbA1c (glycemic control)
• NT-proBNP or BNP (heart failure status - more useful than repeat galectin-3) 11
• Potassium (if on finerenone)

Addressing the Multimorbidity Burden

This patient's constellation of conditions creates a cardio-renal-metabolic syndrome where:

• Elevated galectin-3 reflects systemic fibrosis and inflammation 5, 13
• Each condition accelerates the others
• SGLT2 inhibitors uniquely address all three domains simultaneously 1, 3, 5

The markedly elevated galectin-3 (36.4 ng/mL) indicates she is in the highest-risk quartile where absolute benefit from SGLT2 inhibitors is greatest 3. This is not a biomarker to "treat" but rather a red flag indicating aggressive evidence-based therapy is urgently needed.

The combination of SGLT2 inhibitor + finerenone + optimized ACE/ARB + beta-blocker represents the current evidence-based standard for reducing mortality, hospitalization, and quality of life deterioration in this high-risk phenotype. 1